Abstract

BackgroundDue to the development of diagnostic imaging technology, we have increased chance of detecting multiple primary cancers. However, simultaneous triple cancer is still a very rare finding whose frequency is not yet known. Treatment of simultaneous triple cancer is a clinical challenge because it requires multimodal strategies including surgery, chemotherapy and radiotherapy.Case presentationHere, we present the case of a 74-year-old male with triple cancer involving esophageal and pancreatic cancer, and rectal carcinoma. Each cancer was surgically resectable, but simultaneous resection of all cancers seemed to cause too much surgical stress for the patient. First, we performed a laparoscopic Hartmann’s operation for rectal cancer to minimize the risk of postoperative complications. Then treatment for pancreatic cancer was initiated by administering neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel. The pancreatic tumor shrank in size, so pancreatoduodenectomy was performed. We chose S-1 as adjuvant chemotherapy. The esophageal cancer showed regression during the treatment of the other two cancers, likely because the chemotherapeutic agents administered for pancreatic cancer had some effect on the esophageal cancer. Definitive chemoradiotherapy was selected instead of esophagectomy because the patient had already undergone two major surgeries. The patient is still alive nine months after the whole course of treatment with no sign of recurrence.ConclusionsThe treatment of triple cancer requires an elaborate strategy to determine which cancer has to be dealt with first and which can be treated later. An aggressive multimodal treatment strategy may be an important option for a patient with triple cancer.

Highlights

  • Due to the development of diagnostic imaging technology, we have increased chance of detecting multiple primary cancers

  • The postoperative clinical course was remarkable for a portal vein thrombus (PVT) detected by Contrast-enhanced computed tomography (CE-CT), which was performed on the 5th day after surgery to evaluate abnormally elevated liver enzymes

  • The borderline resectability of the tumor and the possibility of PVT being a tumor embolism led us to the initiation of neoadjuvant chemotherapy (NAC) for pancreatic cancer

Read more

Summary

Background

Due to the development of diagnostic imaging technology, we have increased chance of dealing with multiple primary cancers. The clinical diagnosis was simultaneous advanced triple cancer involving esophageal and pancreatic cancer, and rectal carcinoma. Pancreatic cancer was the prognostic determinant for the patient, rectal obstruction had to be prevented to initiate treatment for pancreatic cancer. The postoperative clinical course was remarkable for a portal vein thrombus (PVT) detected by CE-CT, which was performed on the 5th day after surgery to evaluate abnormally elevated liver enzymes. The borderline resectability of the tumor and the possibility of PVT being a tumor embolism led us to the initiation of neoadjuvant chemotherapy (NAC) for pancreatic cancer. The regimen of gemcitabine plus nab-paclitaxel was started with the expectation of its being effective for both esophageal and pancreatic cancer, and it was administered for 10 courses. The patient is alive with no recurrence nine months after the entire course of treatment

Discussion
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call